TONG REN TANG TECHNOLOGIES CO. LTD. Tong Ren Tang Technologies Co. Ltd. Share Price OTC Markets
Equities
TGRNF
CNE100000585
Pharmaceuticals
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8616 USD | +1.47% |
|
-.--% | -.--% |
| 30/04 | Beijing Tong Ren Tang Gets Nod to Sell Fever Drug in Hong Kong | MT |
| 22/03 | Tong Ren Tang Technologies Co. Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 7.5B 1.04B 86.42B | Sales 2025 * | 8.25B 1.14B 95.08B | Capitalization | 6.9B 955M 79.54B |
|---|---|---|---|---|---|
| Net income 2024 * | 631M 87.36M 7.27B | Net income 2025 * | 674M 93.31M 7.77B | EV / Sales 2024 * | 0.85 x |
| Net cash position 2024 * | 499M 69.14M 5.76B | Net cash position 2025 * | 2.32B 322M 26.77B | EV / Sales 2025 * | 0.56 x |
| P/E ratio 2024 * |
10.9
x | P/E ratio 2025 * |
10.2
x | Employees | 4,101 |
| Yield 2024 * |
3.16% | Yield 2025 * |
3.71% | Free-Float | 45.64% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.47% | ||
| 6 months | +1.47% |
1 year
0.85
0.86
3 years
0.680.86
5 years
0.591.22
10 years
0.592.79
| Managers | Title | Age | Since |
|---|---|---|---|
Jia Fu Chen
CEO | Chief Executive Officer | 55 | 15/23/15 |
Guan Zhao Han
LAW | General Counsel | 45 | - |
Shu Wu Zhao
PRN | Corporate Officer/Principal | 42 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Leung Huel Ting
BRD | Director/Board Member | 71 | 11/00/11 |
Ching Har Chan
BRD | Director/Board Member | 67 | 12/18/12 |
Yuan Jing Zhan
BRD | Director/Board Member | 80 | 12/18/12 |
Tong Ren Tang Technologies Co Ltd is a China-based company mainly engaged in the manufacture and sale of traditional Chinese medicine products. The Company's main businesses includes the production, retail and wholesale of traditional Chinese medicine products and health care products and the provision of traditional Chinese medicine diagnosis and treatment services. The Company is also engaged in the production, processing and acquisition of Chinese herbal medicines, drug sales, medical services and advertising. The Company mainly distributes its products in the domestic market and overseas markets.
Sector
Pharmaceuticals
Calendar
28/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
5.388
CNY
Average target price
6.058
CNY
Spread / Average Target
+12.43%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +42.38% | 6.26B | |
| -15.86% | 4.49B | |
| +6.36% | 3.29B | |
| -11.28% | 3.12B | |
| -3.23% | 2.5B | |
| +45.24% | 1.94B | |
| -7.89% | 1.68B | |
| -0.98% | 1.63B | |
| -11.32% | 1.56B |
- Stock Market
- Equities
- 1666 Stock
- TGRNF Stock
